Financials Hubei Jumpcan Pharmaceutical Co., Ltd.

Equities

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 10/05/2024 am IST			5-day change	1st Jan Change
41.63 ^CNY	-1.49%		+1.19%	+32.45%

19/04	Hubei Jumpcan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
09/04	Hubei Jumpcan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	19,705	17,969	25,173	25,092	28,972	38,375	-	-
Enterprise Value (EV) ¹	19,705	17,969	25,173	25,092	28,972	38,375	38,375	38,375
P/E ratio	12.2 x	13.2 x	14.8 x	11.4 x	10.2 x	12.6 x	11.5 x	10.2 x
Yield	5.09%	-	-	-	-	-	-	-
Capitalization / Revenue	2.84 x	2.91 x	3.3 x	2.79 x	3 x	3.82 x	3.38 x	3.28 x
EV / Revenue	2.84 x	2.91 x	3.3 x	2.79 x	3 x	3.82 x	3.38 x	3.28 x
EV / EBITDA	-	-	11.3 x	9.16 x	8.14 x	10.8 x	10.2 x	8.98 x
EV / FCF	-	-	-	-	-	-	-	-
FCF Yield	-	-	-	-	-	-	-	-
Price to Book	3.23 x	2.35 x	2.79 x	2.21 x	2.17 x	2.4 x	2.1 x	1.74 x
Nbr of stocks (in thousands)	8,14,922	8,88,257	8,88,259	9,21,822	9,21,807	9,21,807	-	-
Reference price ²	24.18	20.23	28.34	27.22	31.43	41.63	41.63	41.63
Announcement Date	12/03/20	16/04/21	19/01/22	19/01/23	09/04/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	6,940	6,165	7,631	8,996	9,655	10,042	11,369	11,709
EBITDA ¹	-	-	2,226	2,740	3,561	3,565	3,759	4,275
EBIT ¹	1,858	1,469	1,933	2,423	3,258	3,504	3,816	4,344
Operating Margin	26.77%	23.83%	25.33%	26.94%	33.75%	34.9%	33.56%	37.1%
Earnings before Tax (EBT) ¹	1,893	1,484	1,950	2,508	3,297	3,544	3,871	4,390
Net income ¹	1,623	1,277	1,719	2,171	2,823	3,047	3,334	3,773
Net margin	23.39%	20.72%	22.53%	24.13%	29.24%	30.34%	29.32%	32.23%
EPS ²	1.990	1.530	1.910	2.390	3.080	3.307	3.618	4.097
Free Cash Flow	-	-	-	-	-	-	-	-
FCF margin	-	-	-	-	-	-	-	-
FCF Conversion (EBITDA)	-	-	-	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-	-	-	-
Dividend per Share ²	1.230	-	-	-	-	-	-	-
Announcement Date	12/03/20	16/04/21	19/01/22	19/01/23	09/04/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt	-	-	-	-	-	-	-	-
Net Cash position	-	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Free Cash Flow	-	-	-	-	-	-	-	-
ROE (net income / shareholders' equity)	28.4%	19.9%	20.5%	21.9%	23%	19%	18.3%	17.2%
ROA (Net income/ Total Assets)	-	-	-	-	-	14.2%	13.8%	13.2%
Assets ¹	-	-	-	-	-	21,458	24,159	28,586
Book Value Per Share ²	7.490	8.630	10.20	12.30	14.50	17.30	19.80	23.90
Cash Flow per Share ²	2.640	2.010	2.130	2.840	3.760	2.760	3.890	4.090
Capex ¹	546	-	-	-	-	306	271	255
Capex / Sales	7.86%	-	-	-	-	3.04%	2.38%	2.17%
Announcement Date	12/03/20	16/04/21	19/01/22	19/01/23	09/04/24	-	-	-

¹CNY in Million²CNY

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

D+

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

41.63 CNY

Average target price

52.36 CNY

Spread / Average Target

+25.77%

	1st Jan change	Capi.
HUBEI JUMPCAN PHARMACEUTICAL CO., LTD.	+32.45%	5.31B
ELI LILLY AND COMPANY	+30.38%	684B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	329B
ABBVIE INC.	+3.73%	284B
ASTRAZENECA PLC	+16.70%	240B
NOVARTIS AG	+8.78%	208B
ROCHE HOLDING AG	-7.93%	200B
AMGEN INC.	+7.68%	166B